Skip to main content

Advertisement

ADVERTISEMENT

Myelodysplastic Syndrome News

News
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
News
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
02/21/2024

Amber Denham

Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology

Advertisement

News
02/09/2024

Amber Denham

Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
01/31/2024

Amber Denham

Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
News
01/11/2024

Amber Denham

Amber Denham
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that...
01/11/2024
Oncology

Advertisement

Conference Coverage
12/09/2023

Janelle Bradley

Janelle Bradley
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show...
12/09/2023
Oncology
Conference Coverage
12/09/2023

Janelle Bradley

Janelle Bradley
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood...
12/09/2023
Oncology
News
10/30/2023

Jordan Kadish

Jordan Kadish
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M...
10/30/2023
Oncology

Advertisement

News
10/26/2023

Jordan Kadish

Jordan Kadish
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA...
10/26/2023
Oncology

Advertisement